Connect Biopharma Holdings Limited (CNTB) - News Archive

In a significant advancement in the management of moderate-to-severe uncontrolled asthma, Connect Biopharma has announced the publication of promising data from a global Phase 2 trial of Rademikibart, their investigatio...

Connect Biopharma Faces Nasdaq Delisting as it Seeks to Reinforce Leadership Amidst Market ChallengesSan Diego, March 28, 2025 Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical compan...

Connect Biopharma Holdings Limited Grants Stock Options to New Executives Connect Biopharma Holdings Limited, a global biopharmaceutical company focused on developing therapies for chronic inflammatory diseases, recentl...

Connect Biopharma Announces Positive Long-Term Data from China Trial, Boosting Prospects for Rademikibart in Atopic Dermatitis TreatmentConnect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical compa...

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 - Conne...